$HOWL
Werewolf Therapeutics, Inc. Stock $howl

$howl Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000178553023000033 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$1.501M	$5.900M
YoY Change	-79.39%	18.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.814M	$4.310M
YoY Change	4.58%	-2.91%
% of Gross Profit
Research & Development	$9.649M	$10.84M
YoY Change	-39.16%	-17.08%
% of Gross Profit
Depreciation & Amortization	$460.0K	$440.0K
YoY Change	10.31%	8.91%
% of Gross Profit
Operating Expenses	$14.46M	$15.15M
YoY Change	-29.32%	-13.48%
Operating Profit		-$9.251M
YoY Change		-26.22%
Interest Expense	$965.0K	$970.0K
YoY Change	-18.15%	63.58%
% of Operating Profit
Other Income/Expense, Net	-$6.000K	$966.0K
YoY Change	-108.57%	62.08%
Pretax Income	-$12.00M	-$8.290M
YoY Change	0.61%	-30.59%
Income Tax
% Of Pretax Income
Net Earnings	-$12.00M	-$8.285M
YoY Change	0.61%	-30.63%
Net Earnings / Revenue	-799.67%	-140.42%
Basic Earnings Per Share		-$0.23
Diluted Earnings Per Share	-$0.33	-$0.23
COMMON SHARES
Basic Shares Outstanding	36.19M shares	35.66M shares
Diluted Shares Outstanding		35.65M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$134.3M	$130.1M
YoY Change	3.89%	-7.37%
Cash & Equivalents	$134.3M	$130.1M
Short-Term Investments
Other Short-Term Assets	$2.677M	$3.300M
YoY Change	-32.35%	-51.73%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$1.350M	$5.911M
Total Short-Term Assets	$138.4M	$139.3M
YoY Change	-1.31%	-8.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.85M	$8.342M
YoY Change	65.18%	-9.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$21.62M	$516.0K
YoY Change	1466.45%	-72.15%
Total Long-Term Assets	$36.46M	$37.13M
YoY Change	81.91%	78.18%
TOTAL ASSETS
Total Short-Term Assets	$138.4M	$139.3M
Total Long-Term Assets	$36.46M	$37.13M
Total Assets	$174.8M	$176.4M
YoY Change	9.1%	2.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.336M	$1.386M
YoY Change	9.42%	-0.14%
Accrued Expenses	$10.47M	$7.967M
YoY Change	-26.03%	-42.82%
Deferred Revenue	$907.0K	$1.800M
YoY Change	-86.05%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.667M	$1.700M
YoY Change
Total Short-Term Liabilities	$19.38M	$14.44M
YoY Change	-19.22%	-48.06%
LONG-TERM LIABILITIES
Long-Term Debt	$32.66M	$37.60M
YoY Change
Other Long-Term Liabilities	$11.43M	$0.00
YoY Change	5881.68%	-100.0%
Total Long-Term Liabilities	$44.08M	$0.00
YoY Change	22979.06%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.38M	$14.44M
Total Long-Term Liabilities	$44.08M	$0.00
Total Liabilities	$63.46M	$63.94M
YoY Change	67.4%	54.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$344.1M	-$332.1M
YoY Change	12.18%	12.65%
Common Stock	$4.000K	$3.000K
YoY Change	33.33%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$111.4M	$112.4M
YoY Change
Total Liabilities & Shareholders Equity	$174.8M	$176.4M
YoY Change	9.1%	2.3%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$12.00M	-$8.285M
YoY Change	0.61%	-30.63%
Depreciation, Depletion And Amortization	$460.0K	$440.0K
YoY Change	10.31%	8.91%
Cash From Operating Activities	-$4.585M	-$7.210M
YoY Change	-61.37%	-50.18%
INVESTING ACTIVITIES
Capital Expenditures	$198.0K	$220.0K
YoY Change	-61.78%	-111.26%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$198.0K	-$220.0K
YoY Change	-61.78%	-88.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.073M	40.00K
YoY Change	622.37%	-99.64%
NET CHANGE
Cash From Operating Activities	-4.585M	-7.210M
Cash From Investing Activities	-198.0K	-220.0K
Cash From Financing Activities	9.073M	40.00K
Net Change In Cash	4.290M	-7.390M
YoY Change	-138.54%	38.13%
FREE CASH FLOW
Cash From Operating Activities	-$4.585M	-$7.210M
Capital Expenditures	$198.0K	$220.0K
Free Cash Flow	-$4.783M	-$7.430M
YoY Change	-61.39%	-40.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-8285000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000	usd
CY2023Q3	us-gaap	Investment Income Net InvestmentIncomeNet	971000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-11943000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	191000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31515000	shares
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1136000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	268000	usd
CY2022Q3	us-gaap	Investment Income Net InvestmentIncomeNet	593000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	3312000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	729000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	966000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	997000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25365000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41880000	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35654000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35654000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29764000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29764000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35335000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35335000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28233000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28233000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	122337000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	103000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8610000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2108000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11982000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	121073000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	31000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	644000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	45000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1930000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	118599000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	29000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2097000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	112443000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	152787000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1745000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	129000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15343000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	139318000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	314000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3339000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1777000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-14594000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	129841000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	87000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11020000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1936000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	93000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-11943000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	130947000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25365000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41880000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6135000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5458000	usd
	us-gaap	Depreciation Depreciation	1304000	usd
	us-gaap	Depreciation Depreciation	687000	usd
	howl	Non Cash Interest Expense NonCashInterestExpense	181000	usd
	howl	Non Cash Interest Expense NonCashInterestExpense	0	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1212000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1265000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-1030000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	253000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	60000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-596000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3398000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1017000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	4300000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-136000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1204000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	241000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-778000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5338000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4677000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5258000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	10801000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1727000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-498000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-191000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	191000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28027000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28726000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	571000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3093000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-571000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3093000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9447000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14761000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	40000000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	143000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	341000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	45000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	230000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49356000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14650000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20758000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17169000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130529000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158830000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151287000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	141661000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1646000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	198000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	307000	usd
	howl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	24000	usd
	howl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	61000	usd
	howl	Stock Option Exercise Receivables In Prepaid Expenses And Other Current Assets StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets	0	usd
	howl	Stock Option Exercise Receivables In Prepaid Expenses And Other Current Assets StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets	-7000	usd
	howl	Leasehold Improvements Paid By Landlord LeaseholdImprovementsPaidByLandlord	0	usd
	howl	Leasehold Improvements Paid By Landlord LeaseholdImprovementsPaidByLandlord	5444000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130100000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7660000	usd
	howl	Increase In Contract With Customer Liability IncreaseInContractWithCustomerLiability	5000000	usd
	howl	Decrease In Contract With Customer Liability DecreaseInContractWithCustomerLiability	10258000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7660000	usd
	howl	Increase In Contract With Customer Liability IncreaseInContractWithCustomerLiability	5000000	usd
	howl	Decrease In Contract With Customer Liability DecreaseInContractWithCustomerLiability	10258000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates and judgments including, but not limited to, those related to revenue recognition, accrued expenses, assumptions used in the valuation of stock-based compensation and income taxes. Actual results could differ from those estimates.</span></div>
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	18400000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5000000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5000000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	4200000	usd
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	4200000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5000000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5000000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1800000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	600000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6500000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1100000	usd
CY2023Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	900000	usd
CY2022Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	4100000	usd
CY2023Q3	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss ContractWithCustomerReceivableAfterAllowanceForCreditLoss	5000000	usd
CY2022Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss ContractWithCustomerReceivableAfterAllowanceForCreditLoss	2800000	usd
	howl	Success Fee Liability Paid SuccessFeeLiabilityPaid	1600000	usd
	howl	Success Fee Liability Paid SuccessFeeLiabilityPaid	1600000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	21200000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129315000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130058000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	157531000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140450000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	210000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	91000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1214000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	21019000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1208000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1211000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130529000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151287000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158830000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	141661000	usd
CY2023Q3	howl	Accrued Manufacturing Current AccruedManufacturingCurrent	1928000	usd
CY2022Q4	howl	Accrued Manufacturing Current AccruedManufacturingCurrent	6674000	usd
CY2023Q3	howl	Accrued Contract Research Current AccruedContractResearchCurrent	1745000	usd
CY2022Q4	howl	Accrued Contract Research Current AccruedContractResearchCurrent	2990000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2666000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3135000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	678000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	613000	usd
CY2023Q3	howl	Success Payment Liability SuccessPaymentLiability	0	usd
CY2022Q4	howl	Success Payment Liability SuccessPaymentLiability	570000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	950000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	170000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7967000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14152000	usd
CY2022Q2	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.045
CY2023Q3	howl	Success Fee Liability Paid SuccessFeeLiabilityPaid	1600000	usd
CY2023Q2	howl	Success Fee Liability Paid SuccessFeeLiabilityPaid	1600000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8667000	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6809000	shares
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2097000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1936000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6135000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5458000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.91
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.35
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.56
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.00
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	11200000	usd
	howl	Sublease Cash Payments Received SubleaseCashPaymentsReceived	1200000	usd
CY2023Q3	us-gaap	Security Deposit Liability SecurityDepositLiability	200000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6856000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5700000	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
howl-20230930_def.xml	Edgar Link	unprocessable
0001785530-23-000033-index-headers.html	Edgar Link	pending
0001785530-23-000033-index.html	Edgar Link	pending
0001785530-23-000033.txt	Edgar Link	pending
0001785530-23-000033-xbrl.zip	Edgar Link	pending
a09302023ex311.htm	Edgar Link	pending
a09302023ex312.htm	Edgar Link	pending
a09302023ex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
howl-20230930.htm	Edgar Link	pending
howl-20230930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
howl-20230930_cal.xml	Edgar Link	unprocessable
howl-20230930_pre.xml	Edgar Link	unprocessable
howl-20230930_lab.xml	Edgar Link	unprocessable
howl-20230930_htm.xml	Edgar Link	completed
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HOWL
Werewolf Therapeutics, Inc. Stock $howl

2023 Q4 Form 10-Q Financial Statement

#000178553023000033 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOWL Werewolf Therapeutics, Inc. Stock $howl

2023 Q4 Form 10-Q Financial Statement

#000178553023000033 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOWL
Werewolf Therapeutics, Inc. Stock $howl